Navigation Links
Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease
Date:5/27/2009

invaluable, and we can now incorporate these insights in a follow-on clinical trial that we are planning to initiate later this year. Our goal remains to significantly improve the symptoms of Parkinson's patients and also to provide the opportunity to delay further disease progression."

About Phase 2 Trial of CERE-120

Ceregene's Phase 2 trial was a double-blind, controlled clinical trial that completed enrollment of 58 patients with advanced Parkinson's disease in October 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in the Phase 2 trial were enrolled across nine leading academic medical centers in the United States, with two thirds of patients receiving CERE-120 and one third enrolled into a control group. Patients received a single administration of CERE-120 via stereotactic neurosurgery to deliver the drug into the putamen region of the brain and were followed for a minimum of 12 months for safety and efficacy, with over half the subjects followed for 15 to 18 months under blinded conditions, allowing longer-term analyses of the therapeutic effects of CERE-120. Ceregene gratefully acknowledges the financial support received from the Michael J. Fox Foundation for Parkinson's Research to help defray some of the costs of the CERE-120 Phase 1 and Phase 2 clinical trials.

About CERE-120 and its Application to Treating Parkinson's Disease

CERE-120 is composed of an adeno-associated virus (AAV) vector carrying the gene for neurturin, a naturally occurring protein known to repair damaged and dying dopamine-secreting neurons, keeping them alive and restoring normal function. Neurturin is a member of the same protein family as glial cell-derived neurotrophic factor (GDNF). The two molecules have similar pharm
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
2. Ceregene Completes Enrollment of Phase 2 Clinical Trial for Parkinsons Disease
3. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
4. NewCardio Medical and Technology Team Presents Two Abstracts at Heart Rhythm Society Conference
5. Trius Presents New Data on Torezolid Antibiotic for Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections
6. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
7. The EntreTech Forum Presents ... PHOTONICS/OPTICS - Understanding the Latest Applications of Light-based Technologies in Medical, Consumer, Industrial, and Defense Sectors
8. Chief Technology Officer for Baxa Corporations Subsidiary, FHT, Inc., Presents at the Fourth Annual unSUMMIT for Bedside Barcoding in Tampa, Florida
9. Dr. Gunther von Hagens HUMAN SAGA Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life.
10. Americans United for Life Represents 28 Bipartisan Montana Legislators Arguing Assisted Suicide Not a Right
11. American Transplant Congress 2009: New Investigator Forum Presents Cutting Edge Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... September 21, 2014 Market ... (CAS 49562-28-9) Industry, 2009-2019 is a professional ... Chinese Fenofibrate (CAS 49562-28-9) industry. The report ... (CAS 49562-28-9) including its classification, application and ... China’s top manufacturers of Fenofibrate (CAS 49562-28-9) ...
(Date:9/21/2014)... September 21, 2014 “Cluster headaches are ... intense and difficult to resolve,” said Steve Young of ... think of a pain that is more intense.” , ... from cluster headaches, or migraines, that medical research is ... serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is ...
(Date:9/21/2014)... September 21, 2014 According to latest ... highest birth rate since 1966 (10.5 births per 1,000 women ... early 40s has risen steadily by 2 percent per year. ... to women aged 50 and over) also rose, the first ... were more than nine times as many first births to ...
(Date:9/20/2014)... Weight Destroyer , a weight loss ... Wren that has already helped tens of thousands of ... like high blood pressure, high cholesterol, and accelerated aging ... investigative review. , “Weight Destroyer is totally turning ... showing people what is truly effective when it comes ...
(Date:9/20/2014)... Increases in household, construction and commercial ... volumes. However, government regulations and higher landfill disposal ... to IBISWorld industry analyst Alen Allday, “over the ... reducing the volume of waste generated, and increasing ... a large proportion of waste generated by households ...
Breaking Medicine News(10 mins):Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Fenofibrate Industry Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Provider of Affordable Health Insurance Points to President,s Suggestion that ... , AVENTURA, Fla., June 23 Cinergy ... programs for the consumer market, expressed its approval with remarks ... , "As politicians from both sides of the aisle ...
... researchers say , TUESDAY, June 23 (HealthDay News) -- A ... a small study shows. , In the new study, researchers ... (PTMA) system, which is installed via a catheter. , In ... from the left atrium into the left ventricle (from the ...
... need for pacemaker, early death, study shows , TUESDAY, ... an electrocardiogram (EKG), until now thought to be insignificant, ... and an increased risk of early death, a new ... PR interval, the right-hand portion of the jagged blip ...
... are overweight or obese have an increased risk of pancreatic ... with a lower overall survival rate for patients with pancreatic ... of JAMA . Pancreatic cancer is the ... women in the United States. As the prevalence of overweight ...
... ... , ... (PRWEB) June 23, 2009 -- Connextions Inc. today announced the appointment of ... responsibility for management of the company,s 12-member development team at its Technology Center in ...
... ... Chester and Delaware Counties Go Back to School , ... Philadelphia (Vocus) June 23, 2009 -- ... will be awarding scholarships, totaling $82,000, to 41 of its members, on Tuesday, June ...
Cached Medicine News:Health News:Cinergy Health Commentary On President Obama's Call for Cost Control, Competition in Health Insurance Arena 2Health News:New Heart Valve Repair System Tested for Safety 2Health News:Electrocardiogram Blip Signals Heart Trouble 2Health News:Electrocardiogram Blip Signals Heart Trouble 3Health News:Being overweight, obese during early adulthood associated with greater risk of pancreatic cancer 2Health News:Being overweight, obese during early adulthood associated with greater risk of pancreatic cancer 3Health News:Connextions, Inc. Strengthens Technology Capabilities with Addition of Highly Regarded IT Executive 2Health News:Connextions, Inc. Strengthens Technology Capabilities with Addition of Highly Regarded IT Executive 3Health News:41 Keystone Mercy Health Plan Members to Receive Scholarships from the Plan's Employees 2
(Date:9/19/2014)... , Sept. 19, 2014 Five MinuteClinic walk-in medical clinics ... metropolitan area. Three clinics opened in Memphis ... A fourth clinic will be added in Springfield ... Bartlett is expected to open October 22.  MinuteClinic is ... the United States . The ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
(Date:9/19/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... ITCA 650 (continuous subcutaneous delivery of exenatide) in type ... the 50 th Annual Meeting of the European ... the open-label, phase 3 FREEDOM-HBL (high baseline) trial showed ... poorly controlled type 2 diabetes. The results were presented ...
Breaking Medicine Technology:MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... 26, 2007 - A new study published ... ("A National Survey of,Physician-Industry Relationships") on the ... the need for,profession-wide and public policy reforms ... that the existing,voluntary PhRMA (Pharmaceutical Research and ...
... 2007 - Aeolus,Pharmaceuticals, Inc. (OTCBB:AOLS) announced today ... of the Journal of Neuroscience a study,by ... National Jewish,Medical and Research Center demonstrating that ... 11207, demonstrated,neuroprotection in an animal model of ...
Cached Medicine Technology:Ties Between Physicians and Drug Companies Still Too Strong: the,Prescription Project Offers Solutions to Prevent Conflicts of,Interest 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 2Study Demonstrating Aeolus Compound's Neuroprotection in,Parkinson's Disease Published in the Journal of Neuroscience 3
... The advanced performance benefits of TiMAX™ ... generation of implants. DePuy ACEs Large Fragment ... biocompatibility and enhanced imaging compatibility over traditional ... unique thread design in the TiMAX bone ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... Fragment System has been conceived and engineered ... and user-friendly instrumentation. The modular system of ... instrumentation is designed to provide the surgeon ... and classic techniques of open reduction and ...
Medicine Products: